Last reviewed · How we verify
Soludronate®
Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts.
Soludronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and disrupting the mevalonate pathway in osteoclasts. Used for Osteoporosis (phase 3 development).
At a glance
| Generic name | Soludronate® |
|---|---|
| Sponsor | Xeolas Pharmaceuticals Limited |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase (indirect); hydroxyapatite binding |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Osteoporosis |
| Phase | Phase 3 |
Mechanism of action
As a bisphosphonate, soludronate localizes to sites of bone resorption and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. This disruption prevents osteoclast function and survival, leading to reduced bone turnover and increased bone mineral density. The drug is designed to treat conditions characterized by excessive bone loss.
Approved indications
- Osteoporosis (phase 3 development)
Common side effects
- Osteonecrosis of the jaw
- Atypical femoral fractures
- Gastrointestinal upset
- Musculoskeletal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Soludronate® CI brief — competitive landscape report
- Soludronate® updates RSS · CI watch RSS
- Xeolas Pharmaceuticals Limited portfolio CI